ECCO 2021

Role of JAKi in IBD: What’s new in 2021?

IL23 inhibiton: Efficacy & Safety Updates

Comparing the different modes of action in IBD: Selection & Positioning

Novel agents: Do we need new drugs or just combinations?

Imaging: routine care vs. clinical trial setting? The predictive value of ultrasonography

Artificial Intelligence in IBD ... Even today a part of clinical care!

What are the therapeutic goals in IBD? Clinical goals vs. patient oriented goals (disease clearance, endoscopic healing, transmural healing, normal QoL, ...)

Therapeutic algorithms: How to define? Transfering trial data into routine care? Hit hard, hit early!

AI: The new frontier in endoscopy interpretation

AI - Has artificial intelligence reached IBD

AI is coming!

Classification through AI is coming!

Intelligenza artificiale: la nuova frontiera in endoscopia per la quantificazione dell'infiammazione intestinale

Künstliche Intelligenz hilfreich bei Auswertung endoskopischer Befunde

AI está llegando!

L'intelligence artificielle arrive dans la RCH !

New Therapeutic Strategies: STARDUST treat-to-target trial with Ustekinumab in Crohn's Disease

SEAVUE - Head-to-head comparison: Applicable for daily practice?

SEAVUE: Early intervention leads to great remission; STARDUST: Treat to Target - better for patients with high endoscopic disease

SAEVUE: The 1st biologic head-to-head trial in Crohn's Disease

SEAVUE: no difference in remission between ustekinumab and adalimumab. Early treatment is most important!

Which treatment for acute/severe UC after steroid failure

The SEAVUE Trial - will it help us to guide and position our treatment in Crohn's disease?

SEAVUE: From efficacy to pharmacoeconomic perspectives

More JAK inhibitors - same questions!

Need for early resection in Crohn's disease is not associated with poor prognosis - long-term follow-up data from Denmark

Welche Therapiestrategie für welches Therapieziel?

Adalimumab vs Ustekinumab: dai risultati di confronto diretto alla partica clinica?

SEAVUE: Early intervention leads to great remission; STARDUST: Treat to Target - better for patients with high endoscopic disease

Enfin un seuil avec l'UCEIS !

Badanie SEAVUE - czy pomoże nam pozycjonować leki biologiczne i poprawić wyniki leczenia choroby Leśniowskiego-Crohna?

Leczenie chirurgiczne na bardzo wczesnym etapie choroby Leśniowskiego-Crohna nie prognozuje niekorzystnego przebiegu choroby w obserwacji długoterminowej

Predictive value of Milan Ultrasound in UC

PREdiCCt: Predictive factors associated with fatigue in IBD

Hot topic: Intestinational ultrasound for disease monitoring in Crohn's Disease

Towards UCEIS cutoff in UC

Liquid biopsy as a novel non-invasive biomarker in IBD

Symsptoms and signs assocation - the value of histology

VARSITY: Epithelial neutrophils are very important actors in Ulcerative Colitis

Liquid biopsy opens exciting window for biomarker monitoring

Prädiktiver Wert des Darmultraschalls bei UC

PREdiCCt: Fatigue assoziierte prädiktive Faktoren

Hot topic: Tarmultralyd til monitorering af Crohn's sygdom

Quel traitement d'entretien en cas de colite aiguë grave cortico-sensible ?

New Therapeutic Treatments in IBD: JAKi

IL-12/23 Blockade: Mechanism of action

New drugs with signifiicant efficacy: ritlecitinib, brepocitinib, upadacitinib

Upadacitinib: Impressive induction data in Ulcerative Colitis

Results form phase 3 induction studies with Upadacitinib in Ulcerative Colitis: U-ACCOMPLISH/U-ACHIEVE

Upadacitinib significantly effective in UC (U-ACCOMPLISH)

IL-23 inhibition with risankizumab effective for biologically treatment naive and preexposed patients (ADVANCE and MOTIVATE)

SELECTION updates: no apparent safety concerns for filgotinib

ADVANCE and MOTIVATE: Risankizumab with fast induction kinetics

VIBRATO: Ritlecitinib and brepocitinib both effective. Ritlecitinib with more benefit from new mode of action.

Neue Daten zu JAK-Inhibitoren

Neue Aspekte zu IL-12 und IL-23-Antikörpern

New drugs with signifiicant efficacy: ritlecitinib, brepocitinib, upadacitinib

Resultaten van de fase 3 inductie studies met upadacitinib in colitis ulcerosa: U-ACCOMPLISH/U-ACHIEVE

Ritlecitinib und Brepocitinib: Neue Targets der JAK-Inhibition bei CU

Anti-IL-23 Antikörper könnten potentielle Game-changer bei MC sein

Providing CLARITY on COVID-19 in IBD

5-ASA - back from the other side? New COVID-19 safety data from the SECURE-IBD cohort

Immune response to anti-SARS-CoV-2 vaccinations in different treatment subgroups of IBD patients. What has been clarified by the CLARITY IBD study so far?

5-ASA - powrót z zaświatów? Nowe dane z badania SECURE-IBD, dotyczące bezpieczeństwa terapii 5-ASA w dobie pandemii COVID-19.

Odpowiedź immunologiczna na szczepienia przeciw SARS-CoV-2 u chorych z IBD. Czy leczenie ma wpływ i co to może oznaczać dla naszych pacjentów?

Wide spectrum of treatments for IBD

Espectro de tratamientos amplio para IBD?

CRAFT UC: Diet more effective than FMT? We need more data

My perspective on ECCO2021

Increasing prevalence of IBD in Brazil

Update ECCO-Guideline on Vaccination and Vaccination Strategy

Fecal transplantation or diet for Ulcerative Colitis?

Appendectomy for Ulcerative Colitis

Stoelgangstransplantatie of dieet voor colitis ulcera?

Stigende forekomst af IBD i Brasilien

Konditionierte Diät ist der FMT bei CU überlegen

El ECCO 2021 desde mi punto de vista

Appendektomi ved patienter med colitis ulcerosa

Neue ECCO-Leitlinie zu Infektionen und Impstrategie